New treatments for peripheral artery disease

被引：1

作者：

Bartholomew, John ^{[1
]}

Bishop, G. Jay ^{[1
]}

机构：

[1] Cleveland Clin, Heart Vasc & Thorac Inst, Dept Cardiovasc Med, ST20,9500 Euclid Ave, Cleveland, OH 44195 USA

来源：

CLEVELAND CLINIC JOURNAL OF MEDICINE | 2020年 / 87卷

关键词：

DUAL ANTIPLATELET THERAPY; CARDIOVASCULAR EVENTS; LOWER-EXTREMITY; TASK-FORCE; MANAGEMENT; ASPIRIN; INTERVENTIONS; CLOPIDOGREL; PREVENTION; VORAPAXAR;

D O I：

10.3949/ccjm.87.s1.03

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The stenosis or occlusion of extremities defining peripheral artery disease (PAD) is a risk factor for adverse cardiovascular events and adverse limb events including amputation. PAD is common, can occur without symptoms or with claudication, and is easily diagnosed. Proper diagnosis and adherence to guideline-directed therapy can reduce the morbidity and potential mortality associated with PAD.

引用

页码：21 / 25

页数：5

共 50 条

[21] Antithrombotic Strategies for Patients With Peripheral Artery Disease
Bonaca, Marc P.
Barnes, Geoffrey D.
Bauersachs, Rupert
Bessada, Youssef
Conte, Michael S.
Dua, Anahita
Hess, Connie N.
Serhal, Maya
Mena-Hurtado, Carlos
Weitz, Jeffrey I.
Beckman, Joshua A.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (10) : 936 - 952
[22] Asymptomatic peripheral artery disease: Silent but deadly
Behroozian, Adam A.
Beckman, Joshua A.
PROGRESS IN CARDIOVASCULAR DISEASES, 2021, 65 : 2 - 8
[23] Rivaroxaban in Peripheral Artery Disease after Revascularization
Bonaca, Marc P.
Bauersachs, Rupert M.
Anand, Sonia S.
Debus, E. Sebastian
Nehler, Mark R.
Patel, Manesh R.
Fanelli, Fabrizio
Capell, Warren H.
Diao, Lihong
Jaeger, Nicole
Hess, Connie N.
Pap, Akos F.
Kittelson, John M.
Gudz, Ivan
Matyas, Lajos
Krievins, Dainis K.
Diaz, Rafael
Brodmann, Marianne
Muehlhofer, Eva
Haskell, Lloyd P.
Berkowitz, Scott D.
Hiatt, William R.
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (21) : 1994 - 2004
[24] Antithrombotic Treatment for Symptomatic Peripheral Artery Disease
Li, Yi-Heng
Yeh, Hung-I
Hwang, Juey-Jen
ACTA CARDIOLOGICA SINICA, 2019, 35 (06) : 557 - 562
[25] Stroke, coronary and peripheral artery disease survey on antithrombotic treatment in Switzerland (START IT)
Keo, Hong H.
Warncke, Cornelius
Hess, Lorenzo
Diehm, Nicolas
Do, Dai-Do
Baumgartner, Iris
SWISS MEDICAL WEEKLY, 2010, 140 (11-12) : 168 - 174
[26] Clinical Practice Recommendations for Antithrombotic Management of Peripheral Artery Disease: An Indian Perspective
Pai, Paresh
Bedi, Varinder S.
Kamerkar, Dhanesh R.
George, Robbie
Rai, Kumud M.
Gupta, P. C.
Sekhar, Raghuram
Balaji, Venugopal
Parakh, Rajiv
Subramanian, S. R.
Thakore, Vijay
Sahu, Tapish
Jindal, Ravul
INDIAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2024, 11 (01) : 4 - 14
[27] Efficacy and Safety of Rivaroxaban Compared with Other Therapies Used in Patients with Peripheral Artery Disease Undergoing Peripheral Revascularization: A Systematic Literature Review and Network Meta-Analysis
Bauersachs, Rupert
Wu, Olivia
Hawkins, Neil
Bowrin, Kevin
Wojciechowski, Piotr
Clay, Emilie
Huelsebeck, Maria
CARDIOVASCULAR THERAPEUTICS, 2021, 2021
[28] New Directions in the Management of Peripheral Artery Disease
Chioncel, Valentin
Brezeanu, Radu
Sinescu, Crina
AMERICAN JOURNAL OF THERAPEUTICS, 2019, 26 (02) : E284 - E293
[29] Contemporary Review of Antithrombotic Therapy in Peripheral Artery Disease
Hess, Connie N.
Bonaca, Marc P.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2020, 13 (10) : E009584
[30] Appropriate Use of Vorapaxar in Patients With Peripheral Artery Disease
Safian, Robert D.
JACC-CARDIOVASCULAR INTERVENTIONS, 2016, 9 (20) : 2165 - 2166

← 1 2 3 4 5 →